Daily Respiratory Research Analysis
Analyzed 162 papers and selected 3 impactful papers.
Summary
Three impactful respiratory-related studies stood out today: durable two-year immunity after a three-dose MVA-MERS-S vaccine regimen, a large UK Biobank cohort linking TyG-BMI to incident VTE (including pulmonary embolism), and validation of multidimensional COPD diagnostic criteria in Japanese smokers that identify high-risk individuals even without airflow limitation. Together, they advance pandemic preparedness, thrombotic risk stratification, and COPD case-finding.
Research Themes
- Durable vaccine-induced immunity against emerging respiratory pathogens
- Metabolic dysregulation as a predictor of venous thromboembolism including pulmonary embolism
- Imaging- and symptom-integrated COPD diagnostics beyond spirometric airflow limitation
Selected Articles
1. Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults.
In an extension of a phase 1b randomized trial, three doses of MVA-MERS-S induced humoral and cellular immunity that persisted for at least 24 months, with antibodies capable of cross-neutralizing spike mutants. The data support the importance of a booster for sustaining long-term immunity against MERS-CoV.
Impact: Demonstrating durable immunity and cross-neutralization in humans strengthens the case for MERS vaccine readiness and informs booster strategies for emerging coronaviruses.
Clinical Implications: Supports the strategic stockpiling and booster planning of MVA-MERS-S for outbreak response; informs correlates of protection and dosing schedules in future phase 2/3 trials.
Key Findings
- Three-dose MVA-MERS-S elicited robust spike-specific antibodies and T cells.
- Humoral and cellular responses persisted for at least 24 months post-third dose.
- Antibodies cross-neutralized MERS-CoV spike mutants.
Methodological Strengths
- Randomized, placebo-controlled, double-blind parent trial with standardized immunologic assays
- Two-year longitudinal follow-up enabling durability assessment
Limitations
- Extension cohort size was modest (n=48) and limited to one site
- Clinical efficacy (protection) was not assessed
Future Directions: Define immune correlates of protection, assess booster intervals and heterologous boosting, and evaluate efficacy in at-risk populations and outbreak settings.
MVA-MERS-S, a vaccine candidate against Middle East respiratory syndrome (MERS), was recently evaluated in a randomized, placebo-controlled, double-blind phase 1b clinical trial to assess its safety, immunogenicity, and optimal dosing in healthy adults in Hamburg and Rotterdam. A three-dose regimen was safe and elicited robust spike-specific antibody responses. We extended this trial to assess the two-year durability of MERS-CoV-specific antibody and T cell responses in 48 study participants of the Hamburg cohort. Our findings show that immune respon
2. Triglyceride-glucose body mass index and risk of incident venous thromboembolism: a prospective cohort study from the UK Biobank.
In 328,208 UK Biobank participants followed a median of 13.64 years, higher TyG-BMI strongly and non-linearly predicted incident VTE, pulmonary embolism, and deep vein thrombosis, with the steepest risk above a threshold of 231.9. Associations were robust across sensitivity analyses and stronger in women, younger individuals, and non-smokers.
Impact: Identifies a practical composite metabolic biomarker that stratifies thrombotic risk at population scale, including events with major respiratory consequences (pulmonary embolism).
Clinical Implications: TyG-BMI could be incorporated into VTE/PE risk assessment to target preventive strategies (e.g., lifestyle, metabolic control) and inform perioperative or immobilization prophylaxis decisions.
Key Findings
- Across TyG-BMI quartiles, VTE incidence increased from 114.0 to 279.1 per 100,000 person-years.
- Highest TyG-BMI quartile had HR 2.10 for VTE, 2.28 for PE, and 1.88 for DVT versus lowest quartile.
- Risk rose sharply in a non-linear fashion beyond TyG-BMI 231.9; associations were consistent in sensitivity analyses.
Methodological Strengths
- Very large prospective cohort with long follow-up and granular covariate adjustment
- Robust analyses including restricted cubic splines, stratification, and population attributable fractions
Limitations
- Observational design precludes causal inference
- Potential residual confounding and measurement variability in metabolic indices
Future Directions: Evaluate TyG-BMI in clinical risk calculators for VTE/PE, test thresholds in diverse populations, and assess whether TyG-BMI-guided interventions reduce thrombotic events.
BACKGROUND: Triglyceride-glucose body mass index (TyG-BMI) is an emerging surrogate indicator of insulin resistance adiposity, which has been demonstrated as a risk factor for various cardiovascular diseases including hypertension, and myocardial infarction. However, association of TyG-BMI with incident VTE remains to be investigated. METHODS: This study included 328,208 participants from the prospective UK Biobank cohort without baseline VTE. The primary outcome was incident VTE, and the second outcomes were incident pulmonary emb
3. Identifying high-risk smokers without airflow limitation using new COPD criteria: pooled analysis of two Japanese cohorts.
Among 517 Japanese smokers, new multidimensional COPD criteria identified individuals at significantly higher exacerbation risk even without airflow limitation (minor-criteria COPD IRR 4.95 vs non-COPD). Higher CAT scores and emphysema percentage independently predicted exacerbations.
Impact: Validates imaging- and symptom-integrated COPD criteria in an Asian population and highlights high-risk smokers missed by spirometry alone.
Clinical Implications: Supports incorporating CT metrics and symptom burden (e.g., CAT) into COPD risk stratification to target prevention and early intervention among smokers without airflow limitation.
Key Findings
- Both major-criteria COPD and minor-criteria-only COPD had higher exacerbation rates than non-COPD (IRR 3.95 and 4.95, respectively).
- Higher CAT scores and emphysema (LAA%) independently predicted exacerbations in COPD.
- A subgroup without spirometric airflow limitation but meeting ≥3 minor criteria had exacerbation risk comparable to classic COPD.
Methodological Strengths
- Pooled analysis from two prospective Japanese cohorts with standardized CT and symptom assessments
- Appropriate modeling of exacerbation counts using negative binomial regression
Limitations
- Retrospective pooled analysis may be subject to selection and information bias
- Generalizability limited to smokers with available CT and CAT data
Future Directions: Prospective validation of decision pathways integrating CT and CAT in primary care, evaluation of targeted interventions in minor-criteria COPD, and cost-effectiveness analyses.
BACKGROUND: Recently proposed multidimensional chronic obstructive pulmonary disease (COPD) diagnostic criteria incorporate computed tomography (CT) findings and symptoms beyond airflow limitation. These criteria, developed using North American cohorts, require validation in Asian populations in which COPD phenotypes differ. We examined whether these criteria identify Japanese smokers at increased exacerbation risk, particularly those without airflow limitation. METHODS: This retrospective analysis pooled data from two prospective Japa